topstockalerts
Relay Therapeutics receives an Overweight rating from JPMorgan, with a $31 price target, reflecting the bank's confidence in its oncology pipeline and the commercial potential of its lead drug candidate, zovegalisib. The company is developing this PI3Kα inhibitor for patients with PI3Kα-mutated breast cancer, as well as vascular anomalies.
JPMorgan's physician surveys indicate that approximately 60%–70% of patients with second-line or later PI3Kα-mutated breast cancer could be eligible for treatment with zovegalisib, suggesting a potentially broad patient population. Phase 1/2 clinical results showed a median progression-free survival of 11.1 months and an objective response rate of 43%, supporting further development of the drug.
Beyond breast cancer, JPMorgan sees a substantial additional opportunity in vascular anomalies, estimating a total addressable market of more than $5 billion and assigning a high probability of clinical and commercial success to the program.
$RLAY
